Assessment of the Treating Physicians’ First-Hand Experience With Handling and Satisfaction of Ofatumumab Therapy: Findings From the PERITIA Survey

Background: Real-world evidence on experience and satisfaction of ofatumumab as a treatment option for relapsing multiple sclerosis (RMS) is limited. Objective: To present cumulative responses from a questionnaire related to first-hand experience of treating physicians on handling and convenience of ofatumumab therapy along with concerns related to COVID-19. Methods: PERITIA was a multicentre survey conducted to collect responses from the ASCLEPIOS I/II trial investigators from Europe via an online questionnaire. Results: Forty-six physicians (Germany, n=14; Spain, n=12; Portugal, n=10; Italy, n=10) completed the survey. Overall, 43% of the physicians considered the benefit-risk ratio of ofatumumab as very good. Over 93% were in favour of ofatumumab self-injection at home and the majority (83%) believed it to be completely true that self-injection of ofatumumab eases the burden for patients in terms of time. All investigators would like to potentially use anti-CD20 therapy as a long-term strategy. Even during the COVID-19 pandemic, physicians were in favour of a self-injectable MS therapy at home over other anti-CD20 therapy infusions. Conclusion: European neurologists who were part of this survey considered the benefit-risk-ratio of ofatumumab as favourable and the monthly self-administered subcutaneous injections offering convenience for patients in the clinical practice.